DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period

Information source: NuPathe Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Migraine Disorders

Intervention: Sumatriptan succinate (Drug); NP101 Study Patch (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: NuPathe Inc.

Official(s) and/or principal investigator(s):
Kerri L Wilks, MD, CPI, Principal Investigator, Affiliation: MD Clinic

Summary

To compare the pharmacokinetics of NP101 with a currently approved oral formulation of Imitrex® (50 mg) in migraine subjects both during an acute migraine attack and during a non-migraine period.

Clinical Details

Official title: A Phase I, Open Label, Single-Dose, Four-Way Crossover Study Comparing the Pharmacokinetics of NP101 (Sumatriptan Iontophoretic Transdermal Patch) With an Oral Formulation of Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period

Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science

Primary outcome: Compare the pharmacokinetics of NP101 with a currently approved formulation of Imitrex in migraine subjects during an acute migraine attack and during a non-migraine period.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Adult male and female subjects, between the ages of 18 to 65 years.

- Subjects with a diagnosis of migraine headache, with or without aura, as defined in

the ICHD-II, and the diagnosis was made before the age of 50.

- The majority of a subject's headaches during a migraine attack are moderate to severe

in intensity.

- Subject has history of regularly occuring migraines, accompanied by nausea or

vomiting.

- Subject has at least one year history of migraine based upon subject testimony.

- Subject will be judged to be in good health, based upon the results of a medical

history, physical examination, vital signs, ECG and laboratory profile.

- Subjects must voluntarily sign and date and Informed Consent agreement approved by an

IRB.

- Subject must have a negative drug screen and re-screen.

- Female subjects of childbearing potential must have a negative pregnancy test at

Screening and Re-Screening.

- Subject has two acceptable patch application sites.

Exclusion Criteria:

- Subject has or plans to start stop, or change treatment (including dose change) of

any medication within one month prior to the subject screening date and through the end of study.

- Subject has less than 2 migraines per month or subject has more than 15 headache

days/month for any of the 3 months prior ot screening.

- Subject who has suspected or confirmed cardiovascular disease that contraindicates

study participation.

- Subject has history of epilepsy or conditions associated with lower seizure

threshold.

- Subject with Raynaud's disease.

- Subject with hemiplegic or basilar migraine.

- Subject with a current diagnosis of major depressive disorder.

- Subject who has taken non-triptan serotonergic drugs including SSRI's, SNRI, TCAs or

MAOI's or preparations containing St. John's Wort within month prior to screening and/or is planning to start any of these medications during the study and through the End of Study Visit.

- Subject is unwilling to discontinue use of PD5 inhibitors (eg. Viagra, Levitra,

Cialis) from screening through End of Study Visit.

- Subject with a history of significant allergy or hypersensitivity to any component of

the NP101 study patch.

- Subject who has any generalized skin irritation or disease including eczema,

psoriasis, melanoma, acne or contact dermatitis.

- Subject has a positive test result for hepatitis B, hepatitis C or is known to be HIV

positive.

- Subjects with moderate or severe hepatic dysfunction defined as SGOT/AST or SGPT/ALT

≥ 2 times the upper limit of normal range, or alkaline phosphatase or total bilirubin ≥ 1. 5 times the upper limit of normal range or if in the opinion of the investigator, the subject's history, physical examination or other laboratory tests suggest hepatic dysfunction.

- Female subjects who are pregnant, breast feeding, or if not of childbearing

potential, is not using or is unwilling to use an effective form of contraception during the study and for a period of 30 days following final dosing.

- Subjects with a known history of tolerability issues with sumatriptan.

- Subject who is considered by the investigator or NuPathe to be an unsuitable

candidate for this study.

- Subject has a history (within 1 year) or current evidence of drug or alcohol abuse or

dependence.

- Subject has participated in a clinical study within 30 days of Screening or is

planning to participate in another clinical study.

- Subject has clinically significant abnormal labs, vital signs or ECG

- Subject is electrically sensitive or who has an implantable electronic device.

Locations and Contacts

MD Clinic, Hallandale Beach, Florida 33009, United States
Additional Information

Starting date: November 2008
Last updated: April 25, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017